Means Investment CO. Inc. Increases Stock Position in Gilead Sciences, Inc. $GILD

Means Investment CO. Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,035 shares of the biopharmaceutical company’s stock after acquiring an additional 344 shares during the quarter. Means Investment CO. Inc.’s holdings in Gilead Sciences were worth $669,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GILD. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Gilead Sciences by 19.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 194,028 shares of the biopharmaceutical company’s stock valued at $21,522,000 after purchasing an additional 31,712 shares in the last quarter. Concurrent Investment Advisors LLC increased its holdings in Gilead Sciences by 40.3% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 52,811 shares of the biopharmaceutical company’s stock worth $5,855,000 after buying an additional 15,164 shares in the last quarter. Johnson Investment Counsel Inc. raised its position in Gilead Sciences by 17.9% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 14,249 shares of the biopharmaceutical company’s stock worth $1,580,000 after buying an additional 2,161 shares during the last quarter. Sivik Global Healthcare LLC lifted its stake in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after acquiring an additional 10,000 shares during the period. Finally, Apollon Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 2.5% during the 2nd quarter. Apollon Wealth Management LLC now owns 35,780 shares of the biopharmaceutical company’s stock valued at $3,967,000 after acquiring an additional 871 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the transaction, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,402,130 in the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $117.18 on Friday. The business has a 50-day simple moving average of $114.65 and a two-hundred day simple moving average of $110.26. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52 week low of $84.17 and a 52 week high of $121.83. The stock has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.